Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis

Overview of attention for article published in Neurotherapeutics, January 2016

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (79th percentile)
Above-average Attention Score compared to outputs of the same age and source (55th percentile)

Mentioned by

twitter: 1 X user

patent: 4 patents

Citations

dimensions_citation: 60 Dimensions

Readers on

mendeley: 94 Mendeley

Summary X Patents Dimensions citations

So far, Altmetric has seen 4 patents that reference this research output.

USE OF CLADRIBINE FOR TREATING AUTOIMMUNE NEUROMUSCULAR DISEASE

Application EP-4292663-A3

European Patent Office

METHODS FOR TREATMENT OF REFRACTORY GENERALIZED MYASTHENIA GRAVIS

Application EP-3909609-A1

European Patent Office

METHODS FOR TREATMENT OF REFRACTORY GENERALIZED MYASTHENIA GRAVIS

Application EP-3463461-A4

European Patent Office

USE OF CLADRIBINE FOR TREATING AUTOIMMUNE NEUROMUSCULAR DISEASE

Application WO-2019016505-A1

World Intellectual Property Organisation (WIPO)